NCT04453124 is a Phase 2 clinical trial of Topical antiseptic treatment in Yaws; Cutaneous, sponsored by Oriol Mitja.

Who is sponsoring NCT04453124?

NCT04453124 is sponsored by Oriol Mitja.

What drugs are being tested in NCT04453124?

Interventions in NCT04453124: Topical antiseptic treatment.

What condition does NCT04453124 study?

NCT04453124 studies Yaws; Cutaneous, Cutaneous Ulcer, Yaws.

Is NCT04453124 still recruiting?

NCT04453124 is currently completed. Last updated 3 September 2020.

Last reviewed 2020-09-03 · How we verify

NCT04453124

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Accessible Low-cost Plant Treatment for Cutaneous Ulcers

Completed Phase 2 Last updated 3 September 2020

What this trial tests

Phase 2 trial testing Topical antiseptic treatment in Yaws; Cutaneous in 150 participants. Completed in 25 November 2019.

Timeline

1 November 2019

Primary endpoint
22 November 2019

25 November 2019

Quick facts

Lead sponsor	Oriol Mitja
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	150
Start date	1 November 2019
Primary completion	22 November 2019
Estimated completion	25 November 2019
Sites	2 locations across Papua New Guinea

Drugs / interventions tested

Topical antiseptic treatment — full drug profile →

Conditions studied

Yaws; Cutaneous — all drugs for Yaws; Cutaneous →
Cutaneous Ulcer — all drugs for Cutaneous Ulcer →
Yaws — all drugs for Yaws →

Sponsor

Oriol Mitja — full company profile →

Who can join

Adults 5 to 15, any sex, with Yaws; Cutaneous or Cutaneous Ulcer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In a search for accessible treatment options, plant medicines used by different communities in Papua New Guinea have been tested to identify the sap of the tree, Ficus septica, as a promising antibacterial agent in vitro. This is an open label clinical trial using an interventional approach, to compare the effect of the antiseptic plant sap and standard topical antiseptic, on the rate of wound development prevention and bacterial growth. If shown to be effective, this readily available plant medicine can provide a zero-cost treatment option in remote areas of PNG.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Oriol Mitja trials

Trials by the same sponsor.

NCT05283954 — Use of a Combined Regimen of Fluoxetine, Prednisolone and Ivermectin in the Treatment of Mild COVID-19 to Prevent Diseas · Phase 2, PHASE3 · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04453124 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Oriol Mitja
Last refreshed: 3 September 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04453124.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing